Pathogenesis of the Limb Manifestations and Exercise Limitations in Peripheral Artery Disease

Circulation Research

Volumn 116, Issue 9, 2015, Pages 1527-1539

  Hiatt, William R ^a   Armstrong, Ehrin J ^a   Larson, Christopher J ^b   Brass, Eric P ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

exercise; metabolism; peripheral artery disease; peripheral vascular diseases; physiopathology; therapeutics

Indexed keywords

OXYGEN; PHOSPHODIESTERASE III INHIBITOR;

ARTERIAL HEMODYNAMICS; ARTICLE; BLOOD RHEOLOGY; CELLULAR PATHOPHYSIOLOGY; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; EXERCISE; EXERCISE HEMODYNAMICS; HEMODYNAMICS; HUMAN; INFLAMMATION; ISCHEMIA; LIMB DISEASE; METABOLIC DISORDER; MICROANGIOPATHY; MITOCHONDRIAL RESPIRATION; MOLECULAR PATHOLOGY; MUSCLE DISEASE; MYOPATHY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REPERFUSION; RESTING HEMODYNAMICS; SKELETAL MUSCLE; SKELETAL MUSCLE METABOLIC ABNORMALITY; SKELETAL MUSCLE STRUCTURAL ABNORMALITY; WALKING; ANKLE BRACHIAL INDEX; BIOLOGICAL MODEL; INTERMITTENT CLAUDICATION; LEG; PERIPHERAL ARTERIAL DISEASE; PHYSIOLOGY; VASCULARIZATION;

ANKLE BRACHIAL INDEX; EXERCISE; HEMODYNAMICS; HUMANS; INTERMITTENT CLAUDICATION; LOWER EXTREMITY; MODELS, CARDIOVASCULAR; MUSCLE, SKELETAL; PERIPHERAL ARTERIAL DISEASE;

EID: 84937596773     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.303566     Document Type: Article

References (162)

1. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368:2004-2013. doi: 10.1056/ NEJMra1216063.
2. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329-1340. doi: 10.1016/S0140-6736(13)61249-0.
3. McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, Chan C, Celic L, Pearce WH, Schneider JR, Sharma L, Clark E, Gibson D, Martin GJ. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA. 2001;286:1599-1606.
4. Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality implications. Circulation. 2006;114:688-699. doi: 10.1161/ CIRCULATIONAHA.105.593442.
5. Hirsch AT, Allison MA, Gomes AS, Corriere MA, Duval S, Ershow AG, Hiatt WR, Karas RH, Lovell MB, McDermott MM, Mendes DM, Nussmeier NA, Treat-Jacobson D; American Heart Association Council on Peripheral Vascular Disease; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology; Council on Epidemiology and Prevention. A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association. Circulation. 2012;125:1449-1472. doi: 10.1161/CIR.0b013e31824c39ba.
6. Goldschmidt-Clermont PJ, Creager MA, Losordo DW, Lorsordo DW, Lam GK, Wassef M, Dzau VJ. Atherosclerosis 2005: recent discoveries and novel hypotheses. Circulation. 2005;112:3348-3353. doi: 10.1161/ CIRCULATIONAHA.105.577460.
7. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180-189. doi: 10.1001/jama.295.2.180.
8. Berger JS, Hochman J, Lobach I, Adelman MA, Riles TS, Rockman CB. Modifiable risk factor burden and the prevalence of peripheral artery disease in different vascular territories. J Vasc Surg. 2013;58:673-81.e1. doi: 10.1016/j.jvs.2013.01.053.
9. Grenon SM, Vittinghoff E, Owens CD, Conte MS, Whooley M, Cohen BE. Peripheral artery disease and risk of cardiovascular events in patients with coronary artery disease: insights from the Heart and Soul Study. Vasc Med. 2013;18:176-184. doi: 10.1177/1358863X13493825.
10. Brevetti G, Giugliano G, Brevetti L, Hiatt WR. Inflammation in peripheral artery disease. Circulation. 2010;122:1862-1875. doi: 10.1161/ CIRCULATIONAHA.109.918417.
11. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Röther J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S; REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197-1206. doi: 10.1001/ jama.297.11.1197.
12. Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation. 2011;124:17-23. doi: 10.1161/CIRCULATIONAHA.110.003954.
13. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-1324.
14. 2011 Writing Group Members; 2005 Writing Committee Members; ACCF/AHA Task Force Members. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;124:2020-2045. doi: 10.1161/ CIR.0b013e31822e80c3.
15. Armstrong EJ, Chen DC, Westin GG, Singh S, McCoach CE, Bang H, Yeo KK, Anderson D, Amsterdam EA, Laird JR. Adherence to guideline- recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3:e000697. doi: 10.1161/JAHA.113.000697.
16. Aboyans V, Criqui MH, Abraham P, et al; American Heart Association Council on Peripheral Vascular Disease; Council on Epidemiology and Prevention; Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012;126:2890-2909. doi: 10.1161/CIR.0b013e318276fbcb.
17. von Ziegler F, Costa MA. The role of CT and MRI in the assessment of peripheral vascular disease. Curr Cardiol Rep. 2007;9:412-419.
18. McDermott MM, Mehta S, Greenland P. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med. 1999;159:387-392.
19. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation. 1990;82:1925-1931.
20. McDermott MM, Guralnik JM, Ferrucci L, Tian L, Liu K, Liao Y, Green D, Sufit R, Hoff F, Nishida T, Sharma L, Pearce WH, Schneider JR, Criqui MH. Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication. Circulation. 2008;117:2484-2491. doi: 10.1161/ CIRCULATIONAHA.107.736108.
21. Hiatt WR, Nawaz D, Regensteiner JG, Hossack KF. The evaluation of exercise performance in patients with peripheral vascular disease. J Cardiopulmonary Rehabil. 1988;12:525-532.
22. Gardner AW. Claudication pain and hemodynamic responses to exercise in younger and older peripheral arterial disease patients. J Gerontol. 1993;48:M231-M236.
23. Gardner AW, Killewich LA, Katzel LI, Womack CJ, Montgomery PS, Otis RB, Fonong T. Relationship between free-living daily physical activity and peripheral circulation in patients with intermittent claudication. Angiology. 1999;50:289-297.
24. Gardner AW, Poehlman ET. Assessment of free-living daily physical activity in older claudicants: validation against the doubly labeled water technique. J Gerontol A Biol Sci Med Sci. 1998;53:M275-M280.
25. McDermott MM, Greenland P, Ferrucci L, Criqui MH, Liu K, Sharma L, Chan C, Celic L, Priyanath A, Guralnik JM. Lower extremity performance is associated with daily life physical activity in individuals with and without peripheral arterial disease. J Am Geriatr Soc. 2002;50:247-255.
26. McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, Pearce WH, Schneider JR, Ferrucci L, Celic L, Taylor LM, Vonesh E, Martin GJ, Clark E. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA. 2004;292:453-461. doi: 10.1001/jama.292.4.453.
27. Wheeler EC, Brenner ZR. Peripheral vascular anatomy, physiology, and pathophysiology. AACN Clin Issues. 1995;6:505-514.
28. Pfitzner J. Poiseuille and his law. Anaesthesia. 1976;31:273-275.
29. Hlavová J, Linhart J, Prerovský I, Ganz V, Fronêk A. Leg blood flow at rest, during and after exercise in normal subjects and in patients with femoral artery occlusion. Clin Sci. 1965;29:555-564.
30. Karayannacos PE, Talukder N, Nerem RM, Roshon S, Vasko JS. The role of multiple noncritical arterial stenoses in the pathogenesis of ischemia. J Thorac Cardiovasc Surg. 1977;73:458-469.
31. Sørlie D, Myhre K. Lower leg blood flow in intermittent claudication. Scand J Clin Lab Invest. 1978;38:171-179.
32. Hiatt WR, Brass EP. Pathophysiology of intermittent claudication. In: Creager MA, Dzau VJ, Loscalzo J, eds. Vascular Medicine: A Companion to Braunwald's Heart Disease. 2nd ed. Philadelphia: Saunders Elsevier; 2013;223-230.
33. Hansen JE, Sue DY, Oren A, Wasserman K. Relation of oxygen uptake to work rate in normal men and men with circulatory disorders. Am J Cardiol. 1987;59:669-674.
34. Hiatt WR, Marsh RC, Brammell HL, Fee C, Horwitz LD. Effect of aerobic conditioning on the peripheral circulation during chronic beta-adrenergic blockade. J Am Coll Cardiol. 1984;4:958-963.
35. Wasserman K. Coupling of external to cellular respiration during exercise: the wisdom of the body revisited. Am J Physiol. 1994;266:E519-E539.
36. Bragadeesh T, Sari I, Pascotto M, Micari A, Kaul S, Lindner JR. Detection of peripheral vascular stenosis by assessing skeletal muscle flow reserve. J Am Coll Cardiol. 2005;45:780-785. doi: 10.1016/j.jacc.2004.11.045.
37. Young DF, Cholvin NR, Kirkeeide RL, Roth AC. Hemodynamics of arterial stenoses at elevated flow rates. Circ Res. 1977;41:99-107.
38. Opolski MP, Pregowski J, Kruk M, Kepka C, Staruch AD, Witkowski A. Advanced 2-dimensional quantitative coronary angiographic analysis for prediction of fractional flow reserve in intermediate coronary stenoses. J Thorac Imaging. 2014;29:217-223. doi: 10.1097/ RTI.0000000000000058.
39. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213-224. doi: 10.1056/NEJMoa0807611.
40. Lotfi AS, Sivalingam SK, Giugliano GR, Ashraf J, Visintainer P. Use of fraction flow reserve to predict changes over time in management of superficial femoral artery. J Interv Cardiol. 2012;25:71-77. doi: 10.1111/j.1540-8183.2011.00691.x.
41. Ledermann HP, Schulte AC, Heidecker HG, Aschwanden M, Jäger KA, Scheffler K, Steinbrich W, Bilecen D. Blood oxygenation level-dependent magnetic resonance imaging of the skeletal muscle in patients with peripheral arterial occlusive disease. Circulation. 2006;113:2929-2935. doi: 10.1161/CIRCULATIONAHA.105.605717.
42. Roseguini BT, Hirai DM, Alencar MC, Ramos RP, Silva BM, Wolosker N, Neder JA, Nery LE. Sildenafil improves skeletal muscle oxygenation during exercise in men with intermittent claudication. Am J Physiol Regul Integr Comp Physiol. 2014;307:R396-R404. doi: 10.1152/ ajpregu.00183.2014.
43. Hickner RC, Fisher JS, Ehsani AA, Kohrt WM. Role of nitric oxide in skeletal muscle blood flow at rest and during dynamic exercise in humans. Am J Physiol. 1997;273:H405-H410.
44. Liao JK, Bettmann MA, Sandor T, Tucker JI, Coleman SM, Creager MA. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res. 1991;68:1027-1034.
45. Schellong SM, Böger RH, Burchert W, Bode-Böger SM, Galland A, Frölich JC, Hundeshagen H, Alexander K. Dose-related effect of intravenous L-arginine on muscular blood flow of the calf in patients with peripheral vascular disease: a H215O positron emission tomography study. Clin Sci (Lond). 1997;93:159-165.
46. Tsao PS, Buitrago R, Chang H, Chen UDI, Reaven GM. Effects of diabetes on monocyte-endothelial interactions and endothelial superoxide production in fructose-induced insulin-resistant and hypertensive rats. Circulation. 1995;92:A2666.
47. Mangiafico RA, Malatino LS, Spada RS, Santonocito M, Messina R, Dell'Arte S, Attinà T. Treadmill exercise-induced release of endothelin-1 in patients with peripheral arterial occlusive disease at Fontaine stage IIb. Int Angiol. 2000;19:14-17.
48. Brevetti G, Silvestro A, Di Giacomo S, Bucur R, Di Donato A, Schiano V, Scopacasa F. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg. 2003;38:374-379.
49. Grenon SM, Chong K, Alley H, Nosova E, Gasper W, Hiramoto J, Boscardin WJ, Owens CD. Walking disability in patients with peripheral artery disease is associated with arterial endothelial function. J Vasc Surg. 2014;59:1025-1034. doi: 10.1016/j.jvs.2013.10.084.
50. Coutinho T, Rooke TW, Kullo IJ. Arterial dysfunction and functional performance in patients with peripheral artery disease: a review. Vasc Med. 2011;16:203-211. doi: 10.1177/1358863X11400935.
51. Silvestro A, Scopacasa F, Ruocco A, Oliva G, Schiano V, Zincarelli C, Brevetti G. Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease. Vasc Med. 2003;8:225-232.
52. Brendle DC, Joseph LJ, Corretti MC, Gardner AW, Katzel LI. Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease. Am J Cardiol. 2001;87:324-329.
53. Januszek R, Mika P, Konik A, Petriczek T, Nowobilski R, Nizankowski R. Effect of treadmill training on endothelial function and walking abilities in patients with peripheral arterial disease. J Cardiol. 2014;64:145-151. doi: 10.1016/j.jjcc.2013.12.002.
54. Baltgalvis KA, White K, Li W, et al. Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice. Am J Physiol Heart Circ Physiol. 2014;306:H1128-H1145. doi: 10.1152/ajpheart.00839.2013.
55. Wu WC, Mohler E 3rd, Ratcliffe SJ, Wehrli FW, Detre JA, Floyd TF. Skeletal muscle microvascular flow in progressive peripheral artery disease: assessment with continuous arterial spin-labeling perfusion magnetic resonance imaging. J Am Coll Cardiol. 2009;53:2372-2377. doi: 10.1016/j.jacc.2009.03.033.
56. Pollak AW, Meyer CH, Epstein FH, Jiji RS, Hunter JR, Dimaria JM, Christopher JM, Kramer CM. Arterial spin labeling MR imaging reproducibly measures peak-exercise calf muscle perfusion: a study in patients with peripheral arterial disease and healthy volunteers. JACC Cardiovasc Imaging. 2012;5:1224-1230. doi: 10.1016/j.jcmg.2012.03.022.
57. Lindner JR, Womack L, Barrett EJ, Weltman J, Price W, Harthun NL, Kaul S, Patrie JT. Limb stress-rest perfusion imaging with contrast ultrasound for the assessment of peripheral arterial disease severity. JACC Cardiovasc Imaging. 2008;1:343-350. doi: 10.1016/j.jcmg.2008.04.001.
58. Anderson JD, Epstein FH, Meyer CH, Hagspiel KD, Wang H, Berr SS, Harthun NL, Weltman A, Dimaria JM, West AM, Kramer CM. Multifactorial determinants of functional capacity in peripheral arterial disease: uncoupling of calf muscle perfusion and metabolism. J Am Coll Cardiol. 2009;54:628-635. doi: 10.1016/j.jacc.2009.01.080.
59. Woodburn KR, Lowe GD, Rumley A, Love J, Pollock JG. Relation of haemostatic, fibrinolytic, and rheological variables to the angiographic extent of peripheral arterial occlusive disease. Int Angiol. 1995;14:346-352.
60. Dormandy JA, Hoare E, Colley J, Arrowsmith DE, Dormandy TL. Clinical, haemodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication. Br Med J. 1973;4:576-581.
61. Lowe GD, Fowkes FG, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation. 1993;87:1915-1920.
62. Fowkes FG, Lowe GD, Housley E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet. 1993;342:84-86.
63. Pande RL, Hiatt WR, Zhang P, Hittel N, Creager MA. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med. 2010;15:181-188. doi: 10.1177/1358863X10361545.
64. Brass EP. Intermittent claudication: new targets for drug development. Drugs. 2013;73:999-1014. doi: 10.1007/s40265-013-0078-3.
65. Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, Forbes WP. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998;27:267-74; discussion 274.
66. Brass EP, Anthony R, Cobb FR, Koda I, Jiao J, Hiatt WR. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006;48:2539-2545. doi: 10.1016/j.jacc.2006.07.064.
67. Brass EP, Cooper LT, Morgan RE, Hiatt WR. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. J Vasc Surg. 2012;55:381-389.e1. doi: 10.1016/j. jvs.2011.09.004.
68. Salhiyyah K, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2012;1:CD005262. doi: 10.1002/14651858.CD005262.pub2.
69. Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby G. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012;99:1630-1638. doi: 10.1002/bjs.8895.
70. de Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev. 2012;12:CD001368. doi: 10.1002/14651858.CD001368.pub4.
71. Barradell LB, Brogden RN. Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging. 1996;8:299-322.
72. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev. 2006;2:CD005263.
73. Hiatt WR, Regensteiner JG, Wolfel EE, Carry MR, Brass EP. Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease. J Appl Physiol (1985). 1996;81:780-788.
74. Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation. 1994;90:1866-1874.
75. Murphy TP, Cutlip DE, Regensteiner JG, et al; CLEVER Study Investigators. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012;125:130-139. doi: 10.1161/CIRCULATIONAHA.111.075770.
76. Hiatt WR, Creager MA, Amato A, Brass EP. Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease. J Cardiopulm Rehabil Prev. 2011;31:125-132. doi: 10.1097/HCR.0b013e3181f1fd65.
77. Pernow B, Zetterquist S. Metabolic evaluation of the leg blood flow in claudicating patients with arterial obstructions at different levels. Scand J Clin Lab Invest. 1968;21:277-287.
78. Szuba A, Oka RK, Harada R, Cooke JP. Limb hemodynamics are not predictive of functional capacity in patients with PAD. Vasc Med. 2006;11:155-163.
79. Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation. 1990;81:602-609.
80. Hynynen MM, Khalil RA. The vascular endothelin system in hypertension- recent patents and discoveries. Recent Pat Cardiovasc Drug Discov. 2006;1:95-108.
81. Vatter H, Seifert V. Ambrisentan, a non-peptide endothelin receptor antagonist. Cardiovasc Drug Rev. 2006;24:63-76. doi: 10.1111/j.1527-3466.2006.00063.x.
82. Hong IS, Coe HV, Catanzaro LM. Macitentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother. 2014;48:538-547. doi: 10.1177/1060028013518900.
83. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, Capeleto B, Hess P, Qiu C, Clozel M. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327:736-745. doi: 10.1124/jpet.108.142976.
84. Forst T, Lübben G, Hohberg C, Kann P, Sachara C, Gottschall V, Friedrich C, Rosskopf R, Pfützner A. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation. 2005;12:543-550. doi: 10.1080/10739680500253402.
85. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol. 2005;46:773-778.
86. Tsuchiya K, Akaza I, Yoshimoto T, Hirata Y. Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in type 2 diabetes. Endocr J. 2009;56:691-698.
87. Edwards AT, Blann AD, Suarez-Mendez VJ, Lardi AM, McCollum CN. Systemic responses in patients with intermittent claudication after treadmill exercise. Br J Surg. 1994;81:1738-1741.
88. Belch JJ, McLaren M, Khan F, Hickman P, Muir AH, Stonebridge PA. The inflammatory process in intermittent claudication. Eur Heart J. 2002;4:B31-B34. doi: 10.1016/S1520-765X(02)90014-3.
89. Belch JJ, Mackay IR, Hill A, Jennings P, McCollum P. Oxidative stress is present in atherosclerotic peripheral arterial disease and further increased by diabetes mellitus. Int Angiol. 1995;14:385-388.
90. Brevetti G, De Caterina M, Martone VD, Ungaro B, Corrado F, Silvestro A, de Cristofaro T, Scopacasa F. Exercise increases soluble adhesion molecules ICAM-1 and VCAM-1 in patients with intermittent claudication. Clin Hemorheol Microcirc. 2001;24:193-199.
91. Signorelli SS, Mazzarino MC, Di Pino L, Malaponte G, Porto C, Pennisi G, Marchese G, Costa MP, Digrandi D, Celotta G, Virgilio V. High circulating levels of cytokines (IL-6 and TNFalpha), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. Vasc Med. 2003;8:15-19.
92. Blann AD, Dobrotova M, Kubisz P, McCollum CN. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost. 1995;74:626-630.
93. Gardner AW, Parker DE, Montgomery PS, Sosnowska D, Casanegra AI, Esponda OL, Ungvari Z, Csiszar A, Sonntag WE. Impaired vascular endothelial growth factor A and inflammation in patients with peripheral artery disease. Angiology. 2014;65:683-690. doi: 10.1177/0003319713501376.
94. Nylaende M, Kroese A, Stranden E, Morken B, Sandbaek G, Lindahl AK, Arnesen H, Seljeflot I. Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med. 2006;11:21-28.
95. McDermott MM, Greenland P, Green D, Guralnik JM, Criqui MH, Liu K, Chan C, Pearce WH, Taylor L, Ridker PM, Schneider JR, Martin G, Rifai N, Quann M, Fornage M. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation. 2003;107:3191-3198. doi: 10.1161/01. CIR.0000074227.53616.CC.
96. McDermott MM, Liu K, Guralnik JM, Ferrucci L, Green D, Greenland P, Tian L, Criqui MH, Lo C, Rifai N, Ridker PM, Zheng J, Pearce W. Functional decline in patients with and without peripheral arterial disease: predictive value of annual changes in levels of C-reactive protein and D-dimer. J Gerontol A Biol Sci Med Sci. 2006;61:374-379.
97. Brass EP, Cooper LT, Hanson P, Hiatt WR. Association of clinical attributes and treadmill walking performance in patients with claudication due to peripheral artery disease. J Vasc Surg. 2013;58:396-403. doi: 10.1016/j.jvs.2012.12.077.
98. Dröse S, Brandt U. Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. Adv Exp Med Biol. 2012;748:145-169. doi: 10.1007/978-1-4614-3573-0-6.
99. Hickman P, Harrison DK, Hill A, McLaren M, Tamei H, McCollum PT, Belch JJ. Exercise in patients with intermittent claudication results in the generation of oxygen derived free radicals and endothelial damage. Adv Exp Med Biol. 1994;361:565-570.
100. Ciuffetti G, Mercuri M, Mannarino E, Ott C, Lombardini R, Pasqualini L, Lupattelli G, Santambrogio L. Free radical production in peripheral vascular disease. A risk for critical ischaemia? Int Angiol. 1991;10:81-87.
101. Melov S, Shoffner JM, Kaufman A, Wallace DC. Marked increase in the number and variety of mitochondrial DNA rearrangements in aging human skeletal muscle. Nucleic Acids Res. 1995;23:4122-4126.
102. Bhat HK, Hiatt WR, Hoppel CL, Brass EP. Skeletal muscle mitochondrial DNA injury in patients with unilateral peripheral arterial disease. Circulation. 1999;99:807-812.
103. Ji LL. Modulation of skeletal muscle antioxidant defense by exercise: role of redox signaling. Free Radic Biol Med. 2008;44:142-152. doi: 10.1016/j.freeradbiomed.2007.02.031.
104. Oh-ishi S, Kizaki T, Nagasawa J, Izawa T, Komabayashi T, Nagata N, Suzuki K, Taniguchi N, Ohno H. Effects of endurance training on superoxide dismutase activity, content and mRNA expression in rat muscle. Clin Exp Pharmacol Physiol. 1997;24:326-332.
105. Vassilakopoulos T, Deckman G, Kebbewar M, Rallis G, Harfouche R, Hussain SN. Regulation of nitric oxide production in limb and ventilatory muscles during chronic exercise training. Am J Physiol Lung Cell Mol Physiol. 2003;284:L452-L457. doi: 10.1152/ajplung.00270.2002.
106. Sumida S, Nakamura H, Yodoi J. Thioredoxin induction of peripheral blood mononuclear cells in mice in response to a single bout of swimming exercise. Gen Physiol Biophys. 2004;23:241-249.
107. Naldini A, Carraro F. Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy. 2005;4:3-8.
108. Gahmberg CG, Tolvanen M, Kotovuori P. Leukocyte adhesion-structure and function of human leukocyte beta2-integrins and their cellular ligands. Eur J Biochem. 1997;245:215-232.
109. Comi G. Treatment of multiple sclerosis: role of natalizumab. Neurol Sci. 2009;30 Suppl 2:S155-S158. doi: 10.1007/s10072-009-0147-2.
110. Schmidt KJ, Büning J, Jankowiak C, Lehnert H, Fellermann K. Crohn's targeted therapy: myth or real goal? Curr Drug Discov Technol. 2009;6:290-298.
111. Enlinomab Acute Stroke Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology. 2001;57:1428-1434.
112. Lin KC, Castro AC. Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol. 1998;2:453-457.
113. Tardif JC, Tanguay JF, Wright SS, Duchatelle V, Petroni T, Grégoire JC, Ibrahim R, Heinonen TM, Robb S, Bertrand OF, Cournoyer D, Johnson D, Mann J, Guertin MC, L'Allier PL. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol. 2013;61:2048-2055. doi: 10.1016/j.jacc.2013.03.003.
114. Kling D, Stucki C, Kronenberg S, Tuerck D, Rhéaume E, Tardif JC, Gaudreault J, Schmitt C. Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab-preclinical and clinical studies. Thromb Res. 2013;131:401-410. doi: 10.1016/j. thromres.2013.02.020.
115. Ahimastos AA, Walker PJ, Askew C, Leicht A, Pappas E, Blombery P, Reid CM, Golledge J, Kingwell BA. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA. 2013;309:453-460. doi: 10.1001/jama.2012.216237.
116. Ahimastos AA, Latouche C, Natoli AK, Reddy-luthmoodoo M, Golledge J, Kingwell BA. Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication. Circ Res. 2014;114:1144-1155. doi: 10.1161/CIRCRESAHA. 114.302420.
117. Shahin Y, Mazari F, Chetter I. Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials. Int J Surg. 2011;9:209-213. doi: 10.1016/j. ijsu.2010.12.006.
118. Brass EP, Koster D, Hiatt WR, Amato A. A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication. Vasc Med. 2013;18:3-12. doi: 10.1177/1358863X12467491.
119. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
120. Hiatt WR, Hirsch AT, Creager MA, Rajagopalan S, Mohler ER, Ballantyne CM, Regensteiner JG, Treat-Jacobson D, Dale RA, Rooke T. Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. Vasc Med. 2010;15:171-179. doi: 10.1177/1358863X09360579.
121. Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481-1486. doi: 10.1161/01. CIR.0000090686.57897.F5.
122. Regensteiner JG, Wolfel EE, Brass EP, Carry MR, Ringel SP, Hargarten ME, Stamm ER, Hiatt WR. Chronic changes in skeletal muscle histology and function in peripheral arterial disease. Circulation. 1993;87:413-421.
123. Askew CD, Green S, Walker PJ, Kerr GK, Green AA, Williams AD, Febbraio MA. Skeletal muscle phenotype is associated with exercise tolerance in patients with peripheral arterial disease. J Vasc Surg. 2005;41:802-807. doi: 10.1016/j.jvs.2005.01.037.
124. McGuigan MR, Bronks R, Newton RU, Sharman MJ, Graham JC, Cody DV, Kraemer WJ. Muscle fiber characteristics in patients with peripheral arterial disease. Med Sci Sports Exerc. 2001;33:2016-2021.
125. Mitchell RG, Duscha BD, Robbins JL, Redfern SI, Chung J, Bensimhon DR, Kraus WE, Hiatt WR, Regensteiner JG, Annex BH. Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial disease. Vasc Med. 2007;12:285-290. doi: 10.1177/1358863X07084858.
126. McDermott MM, Ferrucci L, Guralnik JM, Tian L, Green D, Liu K, Tan J, Liao Y, Pearce WH, Schneider JR, Ridker P, Rifai N, Hoff F, Criqui MH. Elevated levels of inflammation, d-dimer, and homocysteine are associated with adverse calf muscle characteristics and reduced calf strength in peripheral arterial disease. J Am Coll Cardiol. 2007;50:897-905. doi: 10.1016/j.jacc.2007.05.017.
127. Steinacker JM, Opitz-Gress A, Baur S, Lormes W, Bolkart K, Sunder- Plassmann L, Liewald F, Lehmann M, Liu Y. Expression of myosin heavy chain isoforms in skeletal muscle of patients with peripheral arterial occlusive disease. J Vasc Surg. 2000;31:443-449.
128. England JD, Ferguson MA, Hiatt WR, Regensteiner JG. Progression of neuropathy in peripheral arterial disease. Muscle Nerve. 1995;18:380-387. doi: 10.1002/mus.880180403.
129. Garg PK, Liu K, Ferrucci L, Guralnik JM, Criqui MH, Tian L, Sufit R, Nishida T, Tao H, Liao Y, McDermott MM. Lower extremity nerve function, calf skeletal muscle characteristics, and functional performance in peripheral arterial disease. J Am Geriatr Soc. 2011;59:1855-1863. doi: 10.1111/j.1532-5415.2011.03600.x.
130. McDermott MM, Ferrucci L, Guralnik J, Tian L, Liu K, Hoff F, Liao Y, Criqui MH. Pathophysiological changes in calf muscle predict mobility loss at 2-year follow-up in men and women with peripheral arterial disease. Circulation. 2009;120:1048-1055. doi: 10.1161/ CIRCULATIONAHA.108.842328.
131. McDermott MM, Liu K, Tian L, Guralnik JM, Criqui MH, Liao Y, Ferrucci L. Calf muscle characteristics, strength measures, and mortality in peripheral arterial disease: a longitudinal study. J Am Coll Cardiol. 2012;59:1159-1167. doi: 10.1016/j.jacc.2011.12.019.
132. Singh N, Liu K, Tian L, Criqui MH, Guralnik JM, Ferrucci L, Liao Y, McDermott MM. Leg strength predicts mortality in men but not in women with peripheral arterial disease. J Vasc Surg. 2010;52:624-631. doi: 10.1016/j.jvs.2010.03.066.
133. Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, Kumar R, Willins DA, Seehra JS, Sherman ML. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013;47:416-423. doi: 10.1002/mus.23539.
134. Campbell C, Escolar D, Mah J. A phase 2, randomized, placebo controlled, multiple ascending-dose study of ACE-031, a soluble activin receptor Type IIB, in boys with Duchenne muscular dystrophy (DMD). Neurology. 2012;78:P04.088.
135. Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63:561-571. doi: 10.1002/ana.21338.
136. Deleted in proof.
137. Lach-Trifilieff E, Minetti GC, Sheppard K, Ibebunjo C, Feige JN, Hartmann S, Brachat S, Rivet H, Koelbing C, Morvan F, Hatakeyama S, Glass DJ. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014;34:606-618. doi: 10.1128/MCB.01307-13.
138. Grassi B. Regulation of oxygen consumption at exercise onset: is it really controversial? Exerc Sport Sci Rev. 2001;29:134-138.
139. Bauer TA, Regensteiner JG, Brass EP, Hiatt WR. Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease. J Appl Physiol (1985). 1999;87:809-816.
140. Bauer TA, Brass EP, Barstow TJ, Hiatt WR. Skeletal muscle StO2 kinetics are slowed during low work rate calf exercise in peripheral arterial disease. Eur J Appl Physiol. 2007;100:143-151. doi: 10.1007/ s00421-007-0412-0.
141. Barker GA, Green S, Green AA, Walker PJ. Walking performance, oxygen uptake kinetics and resting muscle pyruvate dehydrogenase complex activity in peripheral arterial disease. Clin Sci (Lond). 2004;106:241-249. doi: 10.1042/CS20030244.
142. Kemp GJ, Hands LJ, Ramaswami G, Taylor DJ, Nicolaides A, Amato A, Radda GK. Calf muscle mitochondrial and glycogenolytic ATP synthesis in patients with claudication due to peripheral vascular disease analysed using 31P magnetic resonance spectroscopy. Clin Sci (Lond). 1995;89:581-590.
143. Rouslin W. Mitochondrial complexes I, II, III, IV, and V in myocardial ischemia and autolysis. Am J Physiol. 1983;244:H743-H748.
144. Brass EP, Hiatt WR, Gardner AW, Hoppel CL. Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease. Am J Physiol Heart Circ Physiol. 2001;280:H603-H609.
145. Patel RP, T Cornwell, Darley-Usmar VM. The biochemistry of nitric oxide and peroxynitrite: implications for mitochondrial function. In: Packer L, Cadenas E, eds. Understanding the Process of Aging: The Roles of Mitochondria, Free Radicals, and Antioxidants. New York, NY: Marcel Dekker. 1999;39-56.
146. Bieber LL. Carnitine. Annu Rev Biochem. 1988;57:261-283. doi: 10.1146/annurev.bi.57.070188.001401.
147. Brass EP, Hoppel CL. Relationship between acid-soluble carnitine and coenzyme A pools in vivo. Biochem J. 1980;190:495-504.
148. Hiatt WR, Nawaz D, Brass EP. Carnitine metabolism during exercise in patients with peripheral vascular disease. J Appl Physiol (1985). 1987;62:2383-2387.
149. Hiatt WR, Wolfel EE, Regensteiner JG, Brass EP. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol (1985). 1992;73:346-353.
150. Barker GA, Green S, Green AA, Walker PJ. Walking performance, oxygen uptake kinetics and resting muscle pyruvate dehydrogenase complex activity in peripheral arterial disease. Clin Sci (Lond). 2004;106:241-249. doi: 10.1042/CS20030244.
151. Andreux PA, Houtkooper RH, Auwerx J. Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov. 2013;12:465-483. doi: 10.1038/nrd4023.
152. Hou XY, Green S, Askew CD, Barker G, Green A, Walker PJ. Skeletal muscle mitochondrial ATP production rate and walking performance in peripheral arterial disease. Clin Physiol Funct Imaging. 2002;22:226-232.
153. Russell AP, Feilchenfeldt J, Schreiber S, Praz M, Crettenand A, Gobelet C, Meier CA, Bell DR, Kralli A, Giacobino JP, Dériaz O. Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle. Diabetes. 2003;52:2874-2881.
154. Kramer DM, Ahlsen M, Norrbom J, Jansson E, Hjeltnes N, Gustafsson T, Krook A. Human skeletal muscle fibre type variations correlate with PPARα, PPARd and PGC-1α mRNA. Acta Physiol (Oxf).. 2006;188:207-216.
155. Peters JM, Foreman JE, Gonzalez FJ. Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis. Cancer Metastasis Rev. 2011;30:619-640. doi: 10.1007/ s10555-011-9320-1.
156. Kong X, Wang R, Xue Y, Liu X, Zhang H, Chen Y, Fang F, Chang Y. Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One. 2010;5:e11707. doi: 10.1371/journal.pone.0011707.
157. Ranhotra HS. Estrogen-related receptor alpha and mitochondria: tale of the titans. J Recept Signal Transduct Res. 2014;15:1-5.
158. Procaccio V, Bris C, Chao de la Barca JM, Oca F, Chevrollier A, Amati- Bonneau P, Bonneau D, Reynier P. Perspectives of drug-based neuroprotection targeting mitochondria. Rev Neurol (Paris). 2014;170:390-400. doi: 10.1016/j.neurol.2014.03.005.
159. Shao D, Liu Y, Liu X, Zhu L, Cui Y, Cui A, Qiao A, Kong X, Liu Y, Chen Q, Gupta N, Fang F, Chang Y. PGC-1 beta-regulated mitochondrial biogenesis and function in myotubes is mediated by NRF- 1 and ERR alpha. Mitochondrion. 2010;10:516-527. doi: 10.1016/j. mito.2010.05.012.
160. Pokrywka A, Cholbinski P, Kaliszewski P, Kowalczyk K, Konczak D, Zembron-Lacny A. Metabolic modulators of the exercise response: doping control analysis of an agonist of the peroxisome proliferatoractivated receptor δ (GW501516) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). J Physiol Pharmacol. 2014;65:469-476.
161. Ariazi EA, Clark GM, Mertz JE. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res. 2002;62:6510-6518.
162. Suzuki T, Miki Y, Moriya T, Shimada N, Ishida T, Hirakawa H, Ohuchi N, Sasano H. Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor. Cancer Res. 2004;64:4670-4676. doi: 10.1158/0008-5472.CAN-04-0250.